Tumor Escape

"Tumor Escape" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both cellular immunity (IMMUNITY, CELLULAR) and humoral immunity (ANTIBODY FORMATION), and also costimulatory pathways related to CD28 antigens (CD28 ANTIGENS) and CD80 antigens (B7-1 ANTIGEN).

Descriptor ID	D019139
MeSH Number(s)	G12.900
Concept/Terms	Tumor Escape Tumor Escape Tumor Immune Evasion Evasion, Tumor Immune Evasions, Tumor Immune Immune Evasions, Tumor Tumor Immune Evasions Immune Evasion, Tumor Immune Escape, Tumor Tumor Immune Escape

Below are MeSH descriptors whose meaning is more general than "Tumor Escape".

Biological Sciences [G]
Immune System Phenomena [G12]
Tumor Escape [G12.900]

Below are MeSH descriptors whose meaning is more specific than "Tumor Escape".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Tumor Escape" by people in this website by year, and whether "Tumor Escape" was a major or minor topic of these publications.

Bar chart showing 13 publications over 9 distinct years, with a maximum of 3 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	1	0	1
2013	0	1	1
2015	0	2	2
2019	1	0	1
2020	1	0	1
2021	2	1	3
2022	0	1	1
2023	0	1	1
2024	1	1	2

Below are the most recent publications written about "Tumor Escape" by people in Profiles.

Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT, Bardeesy N. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science. 2024 Jul 12; 385(6705):eadl6173.

View in: PubMed
Pitarresi JR, Fitzgerald KA. Unmasking immune suppression. Science. 2024 Jul 12; 385(6705):140-142.

View in: PubMed
Sari G, Rock KL. Tumor immune evasion through?loss of MHC class-I antigen presentation. Curr Opin Immunol. 2023 08; 83:102329.

View in: PubMed
Varanasi SK, Kaech SM, Bui JD. SnapShot: Cancer immunoediting. Cell. 2022 10 13; 185(21):4038-4038.e1.

View in: PubMed
Emmons TR, Giridharan T, Singel KL, Khan ANH, Ricciuti J, Howard K, Silva-Del Toro SL, Debreceni IL, Aarts CEM, Brouwer MC, Suzuki S, Kuijpers TW, Jongerius I, Allen LH, Ferreira VP, Schubart A, Sellner H, Eder J, Holland SM, Ram S, Lederer JA, Eng KH, Moysich KB, Odunsi K, Yaffe MB, Zsiros E, Segal BH. Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer. Cancer Immunol Res. 2021 07; 9(7):790-810.

View in: PubMed
Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021; 12:636568.

View in: PubMed
Mathewson ND, Ashenberg O, Tirosh I, Gritsch S, Perez EM, Marx S, Jerby-Arnon L, Chanoch-Myers R, Hara T, Richman AR, Ito Y, Pyrdol J, Friedrich M, Schumann K, Poitras MJ, Gokhale PC, Gonzalez Castro LN, Shore ME, Hebert CM, Shaw B, Cahill HL, Drummond M, Zhang W, Olawoyin O, Wakimoto H, Rozenblatt-Rosen O, Brastianos PK, Liu XS, Jones PS, Cahill DP, Frosch MP, Louis DN, Freeman GJ, Ligon KL, Marson A, Chiocca EA, Reardon DA, Regev A, Suv? ML, Wucherpfennig KW. Inhibitory CD161 receptor identified in glioma-infiltrating T?cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26.

View in: PubMed
Luo X, Donnelly CR, Gong W, Heath BR, Hao Y, Donnelly LA, Moghbeli T, Tan YS, Lin X, Bellile E, Kansy BA, Carey TE, Brenner JC, Cheng L, Polverini PJ, Morgan MA, Wen H, Prince ME, Ferris RL, Xie Y, Young S, Wolf GT, Chen Q, Lei YL. HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J Clin Invest. 2020 04 01; 130(4):1635-1652.

View in: PubMed
Kriegsman BA, Vangala P, Chen BJ, Meraner P, Brass AL, Garber M, Rock KL. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression. J Immunol. 2019 10 01; 203(7):1999-2010.

View in: PubMed
Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol. 2016 09; 29(9):1104-12.

View in: PubMed

People

Explore

Similar Concepts

Top Journals